2021 ABCD建议:非糖尿病专科医生应用SGLT2抑制剂治疗2型糖尿病

2021-05-02 Clin Med (Lond).2021 May;21(3):204-210.

2021年1月,英国临床糖尿病专家协会(ABCD)联合英国糖尿病联合会共同发布了非糖尿病专科医生应用SGLT2抑制剂治疗2型糖尿病的建议。钠葡萄糖共转运体2(SGLT2)抑制剂是目前公认的治疗2型糖尿

中文标题:

2021 ABCD建议:非糖尿病专科医生应用SGLT2抑制剂治疗2型糖尿病

英文标题:

Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes

发布机构:

发布日期:

2021-05-02

简要介绍:

2021年1月,英国临床糖尿病专家协会(ABCD)联合英国糖尿病联合会共同发布了非糖尿病专科医生应用SGLT2抑制剂治疗2型糖尿病的建议。钠葡萄糖共转运体2(SGLT2)抑制剂是目前公认的治疗2型糖尿病的药物,本文主要针对非糖尿病专科医生应用SGLT2抑制剂治疗2型糖尿病患者提供指导建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 ABCD建议:非糖尿病专科医生应用SGLT2抑制剂治疗2型糖尿病.pdf)] GetToolGuiderByIdResponse(projectId=1, id=a73731c002108a9a, title=2021 ABCD建议:非糖尿病专科医生应用SGLT2抑制剂治疗2型糖尿病, enTitle=Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes, guiderFrom=Clin Med (Lond).2021 May;21(3):204-210., authorId=0, author=, summary=2021年1月,英国临床糖尿病专家协会(ABCD)联合英国糖尿病联合会共同发布了非糖尿病专科医生应用SGLT2抑制剂治疗2型糖尿病的建议。钠葡萄糖共转运体2(SGLT2)抑制剂是目前公认的治疗2型糖尿, cover=https://img.medsci.cn/2021529/1622302873635_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Sun May 02 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p style="color: #373737;">2021年1月,英国临床糖尿病专家协会(ABCD)联合英国糖尿病联合会共同发布了非糖尿病专科医生应用SGLT2抑制剂治疗2型糖尿病的建议。钠葡萄糖共转运体2(SGLT2)抑制剂是目前公认的治疗2型糖尿病的药物,本文主要针对非糖尿病专科医生应用SGLT2抑制剂治疗2型糖尿病患者提供指导建议。</p>, tagList=[TagDto(tagId=2052, tagName=2型糖尿病)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=2052, guiderKeyword=2型糖尿病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11511, appHits=226, showAppHits=0, pcHits=500, showPcHits=11285, likes=1, shares=12, comments=15, approvalStatus=1, publishedTime=Sun May 30 00:27:37 CST 2021, publishedTimeString=2021-05-02, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat May 29 23:41:20 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 05:52:48 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 ABCD建议:非糖尿病专科医生应用SGLT2抑制剂治疗2型糖尿病.pdf)])
2021 ABCD建议:非糖尿病专科医生应用SGLT2抑制剂治疗2型糖尿病.pdf
下载请点击:
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1080652, encodeId=5925108065254, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:55:15 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055377, encodeId=a5fe10553e7af, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973e5603541, createdName=ms8000000025759398, createdTime=Mon Sep 27 15:08:36 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051050, encodeId=fa2e105105057, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973e5603541, createdName=ms8000000025759398, createdTime=Tue Sep 14 10:57:21 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003291, encodeId=d5151003291d8, content=需要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/c93b12a678ed417d9423f537c3ddbbfe/afd61f202f6d4ca69a2b12097a408ab9.jpg, createdBy=1f805452595, createdName=璐仔, createdTime=Wed Jul 28 11:44:33 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995587, encodeId=612f99558e72, content=正需要了,谢谢了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/nJT9n2Q05bA9kkSaLibf9dPLjU9XbcuribJLexGbxp0ppt5umm9dtzyic1cT5pb7ibFbdOZ6EK6l3WprMzicxenuoNw/0, createdBy=70af2192394, createdName=李婵, createdTime=Sat Jul 03 06:55:57 CST 2021, time=2021-07-03, status=1, ipAttribution=)]
    2021-12-16 龙珠

    学习好资料

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1080652, encodeId=5925108065254, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:55:15 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055377, encodeId=a5fe10553e7af, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973e5603541, createdName=ms8000000025759398, createdTime=Mon Sep 27 15:08:36 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051050, encodeId=fa2e105105057, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973e5603541, createdName=ms8000000025759398, createdTime=Tue Sep 14 10:57:21 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003291, encodeId=d5151003291d8, content=需要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/c93b12a678ed417d9423f537c3ddbbfe/afd61f202f6d4ca69a2b12097a408ab9.jpg, createdBy=1f805452595, createdName=璐仔, createdTime=Wed Jul 28 11:44:33 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995587, encodeId=612f99558e72, content=正需要了,谢谢了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/nJT9n2Q05bA9kkSaLibf9dPLjU9XbcuribJLexGbxp0ppt5umm9dtzyic1cT5pb7ibFbdOZ6EK6l3WprMzicxenuoNw/0, createdBy=70af2192394, createdName=李婵, createdTime=Sat Jul 03 06:55:57 CST 2021, time=2021-07-03, status=1, ipAttribution=)]
    2021-09-27 ms8000000025759398

    不错不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1080652, encodeId=5925108065254, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:55:15 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055377, encodeId=a5fe10553e7af, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973e5603541, createdName=ms8000000025759398, createdTime=Mon Sep 27 15:08:36 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051050, encodeId=fa2e105105057, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973e5603541, createdName=ms8000000025759398, createdTime=Tue Sep 14 10:57:21 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003291, encodeId=d5151003291d8, content=需要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/c93b12a678ed417d9423f537c3ddbbfe/afd61f202f6d4ca69a2b12097a408ab9.jpg, createdBy=1f805452595, createdName=璐仔, createdTime=Wed Jul 28 11:44:33 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995587, encodeId=612f99558e72, content=正需要了,谢谢了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/nJT9n2Q05bA9kkSaLibf9dPLjU9XbcuribJLexGbxp0ppt5umm9dtzyic1cT5pb7ibFbdOZ6EK6l3WprMzicxenuoNw/0, createdBy=70af2192394, createdName=李婵, createdTime=Sat Jul 03 06:55:57 CST 2021, time=2021-07-03, status=1, ipAttribution=)]
    2021-09-14 ms8000000025759398

    不错不错

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1080652, encodeId=5925108065254, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:55:15 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055377, encodeId=a5fe10553e7af, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973e5603541, createdName=ms8000000025759398, createdTime=Mon Sep 27 15:08:36 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051050, encodeId=fa2e105105057, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973e5603541, createdName=ms8000000025759398, createdTime=Tue Sep 14 10:57:21 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003291, encodeId=d5151003291d8, content=需要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/c93b12a678ed417d9423f537c3ddbbfe/afd61f202f6d4ca69a2b12097a408ab9.jpg, createdBy=1f805452595, createdName=璐仔, createdTime=Wed Jul 28 11:44:33 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995587, encodeId=612f99558e72, content=正需要了,谢谢了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/nJT9n2Q05bA9kkSaLibf9dPLjU9XbcuribJLexGbxp0ppt5umm9dtzyic1cT5pb7ibFbdOZ6EK6l3WprMzicxenuoNw/0, createdBy=70af2192394, createdName=李婵, createdTime=Sat Jul 03 06:55:57 CST 2021, time=2021-07-03, status=1, ipAttribution=)]
    2021-07-28 璐仔

    需要

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1080652, encodeId=5925108065254, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:55:15 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055377, encodeId=a5fe10553e7af, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973e5603541, createdName=ms8000000025759398, createdTime=Mon Sep 27 15:08:36 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051050, encodeId=fa2e105105057, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973e5603541, createdName=ms8000000025759398, createdTime=Tue Sep 14 10:57:21 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003291, encodeId=d5151003291d8, content=需要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210728/c93b12a678ed417d9423f537c3ddbbfe/afd61f202f6d4ca69a2b12097a408ab9.jpg, createdBy=1f805452595, createdName=璐仔, createdTime=Wed Jul 28 11:44:33 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995587, encodeId=612f99558e72, content=正需要了,谢谢了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/nJT9n2Q05bA9kkSaLibf9dPLjU9XbcuribJLexGbxp0ppt5umm9dtzyic1cT5pb7ibFbdOZ6EK6l3WprMzicxenuoNw/0, createdBy=70af2192394, createdName=李婵, createdTime=Sat Jul 03 06:55:57 CST 2021, time=2021-07-03, status=1, ipAttribution=)]
    2021-07-03 李婵

    正需要了,谢谢了

    0

拓展阅读

2014 ADS立场声明:2型糖尿病血糖管理法则

澳大利亚糖尿病协会(ADS,Australian Diabetes Society) · 2014-12-11

2015 AHA/ADA科学声明:成人2型糖尿病患者心血管疾病的预防(更新版)

美国糖尿病学会(ADA,American Diabetes Association) · 2015-08-05

2015 ADA/AADE/AND联合声明:2型糖尿病的自我管理教育和支持

美国糖尿病学会(ADA,American Diabetes Association) · 2015-06-05

2013 中国2型糖尿病防治指南(2013年版)

中华医学会糖尿病学分会(CDS,Chinese Diabetes Society) · 2014-08-16